ABSTRACT
Novel fatty acid-bile acid conjugates (1a-1k) were designed and synthesized by coupling of the fatty acids to the 3-OH of bile acids using lysine for linkage. In the conjugates, the 24-COOH of the bile acids was kept intact to preserve liver-specific recognition. The ability of the newly synthesized conjugates (at 100 mg/kg dosage) to reduce total cholesterol (TC) and triglyceride (TG) levels in mice fed with high-fat diet (HFD) was evaluated. Conjugates of stearic acid with cholic acid and palmitic acid with ursodeoxycholic acid (at dosages of 50, 100, and 200 mg/kg) were further evaluated to determine their ability to reduce aspartate aminotransferase (AST), alanine aminotransferase (ALT), TC, and TG levels in mice fed with HFD. All conjugates showed potent hypolipidemic activity. Further investigation revealed that compounds 1c and 1 g not only dose-dependently reduced serum levels of TC and TG, but also inhibited the elevation of serum AST and ALT levels in mice fed with HFD. Thus, compounds 1c and 1 g are promising hypolipidemic agents with hepatocyte protective effects against HFD-induced liver damage.
Subject(s)
Bile Acids and Salts/administration & dosage , Fatty Acids/administration & dosage , Hyperlipidemias/drug therapy , Hypolipidemic Agents/administration & dosage , Liver/drug effects , Animals , Bile Acids and Salts/chemistry , Cholesterol/blood , Diet, High-Fat/adverse effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Fatty Acids/chemistry , Humans , Hyperlipidemias/blood , Hyperlipidemias/etiology , Hyperlipidemias/pathology , Hypolipidemic Agents/chemistry , Lipid Metabolism/drug effects , Liver/metabolism , Liver/pathology , Liver Function Tests , Lysine/chemistry , Mice , Triglycerides/bloodABSTRACT
BACKGROUND: Diabetic neuropathic pain (DNP) is a common and distressing complication in patients with diabetes, and the underlying mechanism remains unclear. Tricyclic antidepressants (TCAs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line drugs for DNP. Ammoxetine is a novel and potent SNRI that exhibited a strong analgesic effect on models of neuropathic pain, fibromyalgia-related pain, and inflammatory pain in our primary study. The present study was undertaken to investigate the chronic treatment properties of ammoxetine on DNP and the underlying mechanisms for its effects. METHODS: The rat model of DNP was established by a single streptozocin (STZ) injection (60 mg/kg). Two weeks after STZ injection, the DNP rats were treated with ammoxetine (2.5, 5, and 10 mg/kg/day) for 4 weeks. The mechanical allodynia and locomotor activity were assayed to evaluate the therapeutic effect of ammoxetine. In mechanism study, the activation of microglia, astrocytes, the protein levels of pro-inflammatory cytokines, the mitogen-activated protein kinases (MAPK), and NF-κB were evaluated. Also, microglia culture was used to assess the direct effects of ammoxetine on microglial activation and the signal transduction mechanism. RESULTS: Treatment with ammoxetine for 4 weeks significantly relieved the mechanical allodynia and ameliorated depressive-like behavior in DNP rats. In addition, DNP rats displayed increased activation of microglia in the spinal cord, but not astrocytes. Ammoxetine reduced the microglial activation, accumulation of pro-inflammatory cytokines, and activation of p38 and c-Jun N-terminal kinase (JNK) in the spinal cord of DNP rats. Furthermore, ammoxetine displayed anti-inflammatory effects upon challenge with LPS in BV-2 microglia cells. CONCLUSION: Our results suggest that ammoxetine may be an effective treatment for relieving DNP symptoms. Moreover, a reduction in microglial activation and pro-inflammatory release by inhibiting the p-p38 and p-JNK pathways is involved in the mechanism.
Subject(s)
Benzodioxoles/therapeutic use , Diabetic Neuropathies/complications , Diabetic Neuropathies/drug therapy , Hypoglycemic Agents/therapeutic use , Microglia/drug effects , Myelitis , Propylamines/therapeutic use , Animals , Benzodioxoles/chemistry , Calcium-Binding Proteins/metabolism , Cell Line, Transformed , Diabetic Neuropathies/chemically induced , Disease Models, Animal , Dose-Response Relationship, Drug , Duloxetine Hydrochloride/therapeutic use , Exploratory Behavior/drug effects , Hyperalgesia/drug therapy , Hyperalgesia/physiopathology , Hypoglycemic Agents/chemistry , Lipopolysaccharides/pharmacology , Locomotion/drug effects , Microfilament Proteins/metabolism , Myelitis/drug therapy , Myelitis/etiology , Myelitis/pathology , Propylamines/chemistry , Rats , Streptozocin/toxicityABSTRACT
Our previous study indicated that 071031B, a novel potential serotonin and norepinephrine reuptake inhibitor, showed robust antidepressant activity in multiple depression models, and could simultaneously inhibit 5-HT and NE reuptake in vitro. The present study was to evaluate the effects of 071031B on monoamine system in vivo, by using pharmacological models, including 5-HTP induced head-twitch test, yohimbine toxicity potentiation test, and reserpine induced hypothermia test, and determining monoamine transmitter levels in reserpine induced monoamine depletion model or chronic unpredictable stress (CUS) model. Results in pharmacological models indicated that acute administration of 071031B at 5-20 mg/kg significantly enhanced 5-HTP induced head-twitch behavior, potentiated yohimbine induced lethal rate, and reversed reserpine induced hypothermia. Further monoamine assays demonstrated that acute or chronic administration of 071031B at 10 or 20 mg/kg increased 5-HT and/or NE levels in various brain regions in reserpine or CUS induced monoamine depletion models, respectively, without effect on DA and its metabolites. Our results revealed that 071031B produces potent inhibition of 5-HT and NE reuptake in vivo.
Subject(s)
Antidepressive Agents , Benzodioxoles/pharmacology , Biogenic Monoamines/metabolism , Norepinephrine/metabolism , Selective Serotonin Reuptake Inhibitors , Serotonin/metabolism , Thiophenes/pharmacology , Animals , Benzodioxoles/administration & dosage , Brain/metabolism , Hypothermia/chemically induced , Male , Mice, Inbred ICR , Rats, Sprague-Dawley , Reserpine , Thiophenes/administration & dosage , Yohimbine/toxicityABSTRACT
Three series of apigenin derivatives have been prepared by coupling the carboxyl alkyl group to 4'-, 5- or 7-hydroxyl groups of apigenin respectively. Preliminary biological evaluation in vitro revealed that xanthine oxidase inhibitory activity was improved by modifications at 4'-position and decreased by similar modifications at 5-, 7-positions while α-glucosidase inhibitory activity was maintained by modifications at 5-, 7-positions but lost by modifications at 4'-position. Administration (ip) of 7e markedly lowered serum uric acid levels in potassium oxonate induced hyperuricemic mouse model and administration (p.o.) of 11d or 11e effectively suppressed the elevation of serum glucose in the oral sucrose tolerance test in mice, while apigenin were not significantly effective in both tests.
Subject(s)
Apigenin/chemistry , Glycoside Hydrolase Inhibitors/chemistry , Hypoglycemic Agents/chemistry , Xanthine Oxidase/antagonists & inhibitors , alpha-Glucosidases/chemistry , Animals , Apigenin/metabolism , Apigenin/therapeutic use , Disease Models, Animal , Drug Evaluation, Preclinical , Flavonoids/chemistry , Glucose Tolerance Test , Glycoside Hydrolase Inhibitors/metabolism , Glycoside Hydrolase Inhibitors/therapeutic use , Hyperuricemia/chemically induced , Hyperuricemia/drug therapy , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/therapeutic use , Infusions, Parenteral , Mice , Protein Binding , Structure-Activity Relationship , Uric Acid/blood , Xanthine Oxidase/metabolism , alpha-Glucosidases/metabolismABSTRACT
Cancer stem cells (CSCs) are reported to play essential roles in chemoresistance and metastasis. Pathways regulating CSC self-renewal and proliferation, such as Hedgehog, Notch, Wnt/ß-catenin, TGF-ß, and Myc, may be potential therapeutic targets. Here, a functional screening from the focused library with 365 compounds is performed by a step-by-step strategy. Among these candidate molecules, phenyl-2-pyrimidinyl ketone 4-allyl-3-amino selenourea (CU27) is chosen for further identification because it proves to be the most effective compound over others on CSC inhibition. Through ingenuity pathway analysis, it is shown CU27 may inhibit CSC through a well-known stemness-related transcription factor c-Myc. Gene set enrichment analysis, dual-luciferase reporter assays, expression levels of typical c-Myc targets, molecular docking, surface plasmon resonance, immunoprecipitation, and chromatin immunoprecipitation are conducted. These results together suggest CU27 binds c-Myc bHLH/LZ domains, inhibits c-Myc-Max complex formation, and prevents its occupancy on target gene promoters. In mouse models, CU27 significantly sensitizes sorafenib-resistant tumor to sorafenib, reduces the primary tumor size, and inhibits CSC generation, showing a dramatic anti-metastasis potential. Taken together, CU27 exerts inhibitory effects on CSC and CSC-associated traits in hepatocellular carcinoma (HCC) via c-Myc transcription activity inhibition. CU27 may be a promising therapeutic to treat sorafenib-resistant HCC.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Selenium Compounds , Selenium , Animals , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/genetics , Cell Line, Tumor , Early Detection of Cancer , Liver Neoplasms/drug therapy , Liver Neoplasms/genetics , Mice , Molecular Docking Simulation , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Selenium/metabolism , Selenium/pharmacology , Selenium Compounds/metabolism , Selenium Compounds/pharmacology , Sorafenib/metabolism , Sorafenib/pharmacologyABSTRACT
We report herein the design and synthesis of novel 1-[3-(dimethylamino)propyl]indolin-2-one derivatives based on the structural features of Sunitinib, a known multitargeted receptor tyrosine kinase inhibitor, and TMP-20, a previously discovered compound with good antitumor activity in our lab. These newly synthesized derivatives were evaluated for in vitro activity against five human cancer cell lines and VEGF/bFGF-stimulated HUVECs. Results revealed that all of the target compounds 1a-p show potent antitumor activity, compounds 1e-h (IC(50)'s: 0.45-5.08 µM) are more active than Sunitinib (IC(50)'s: 1.35-6.61 µM), and the most active compound 1 h (IC(50): 0.47-3.11 µM) is 2.1-4.6-fold more potent than Sunitinib against all five cancer cell lines. In addition, like Sunitinib, 1a-p have higher selectivity on VEGF-stimulated HUVEC other than bFGF-stimulated HUVEC.
Subject(s)
Amides/chemical synthesis , Amides/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Drug Design , Amides/chemistry , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Halogens/chemistry , Humans , Indoles/chemistry , Inhibitory Concentration 50 , Molecular Structure , Pyrroles/chemistry , SunitinibABSTRACT
Human rhinovirus (HRV) is the most important etiologic agent causing common colds. No effective anti-HRV agents are currently available. In this paper we describe the synthesis and the evaluation of novel chloropyridazine derivatives (compounds 5a-g) as potent human rhinovirus (HRV) capsid-binding inhibitors. Results showed that compound 5e and 5f exhibited effective anti-HRV activity against HRV-2 and HRV-14. In addition, compound 5e and 5f showed lower cytotoxicity than Pirodavir.
Subject(s)
Antiviral Agents/chemical synthesis , Capsid Proteins/antagonists & inhibitors , Pyridazines/chemical synthesis , Rhinovirus/drug effects , Antiviral Agents/pharmacology , Common Cold/drug therapy , Humans , Pyridazines/pharmacology , Structure-Activity RelationshipABSTRACT
Our previous study indicated that a chiral compound 071031B was a novel serotonin and noradrenaline reuptake inhibitor with superior antidepressant activity compared to duloxetine. The present study aimed to investigate chiral pharmacology differences of 071031B enantiomers, S-071031B and R-071031B, and disclose mechanisms underlying the behavioral differences based on target profiles and pharmacokinetic profiles. In vivo behavioral tests indicated that S-071031B was more potent than R-071031B in two depression models (the forced swimming test in mice and rats) and two pain models (the acetic acid-induced writhing and formalin tests in mice). In vitro assays revealed that both S-071031B and R-071031B showed high affinity for human serotonin transporters and norepinephrine transporters with equal potency, and showed consistently equipotent inhibitory effects on serotonin and norepinephrine uptake. Pharmacokinetic studies demonstrated that oral availability and hepatic metabolism, rather than pH stability, intestinal transport, and plasma binding, contributed to enantiomers' behavioral differences. Based on these findings, it is suggested that S-071031B is a more active enantiomer, and the differential pharmacokinetic profiles, but not target affinity, contribute to differences of S-071031B and R-071031B in behavioral pharmacology. Moreover, current PK-PD study may provide positive exploration for chiral antidepressants development.
Subject(s)
Benzodioxoles/pharmacology , Benzodioxoles/pharmacokinetics , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics , Serotonin/metabolism , Thiophenes/pharmacology , Thiophenes/pharmacokinetics , Animals , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Depression/drug therapy , Depression/metabolism , Depressive Disorder/drug therapy , Depressive Disorder/metabolism , Duloxetine Hydrochloride/pharmacokinetics , Duloxetine Hydrochloride/pharmacology , Male , Mice , Mice, Inbred ICR , Norepinephrine/metabolism , Norepinephrine Plasma Membrane Transport Proteins/pharmacokinetics , Norepinephrine Plasma Membrane Transport Proteins/pharmacology , Rats , Rats, Sprague-Dawley , Serotonin Plasma Membrane Transport Proteins/metabolism , Swimming/physiologyABSTRACT
AIMS: The present study was conducted to evaluate the antidepressant-like effects of ZBH2012001, a novel potential serotonin and norepinephrine reuptake inhibitor (SNRI). METHODS: Competitive binding assays, calcium flow, and cAMP detection methods were used to determine the affinity of ZBH2012001 for serotonin transporters (SERTs) and norepinephrine transporters (NETs), as well as its selectivity over dopamine transporters (DATs) and 16 other G-protein-coupled receptors (GPCRs) or iron channels. The antidepressant-like effects of ZBH2012001 were determined using the tail suspension test, forced swim test, and learned helplessness paradigm. The pharmacokinetics and acute toxicity of ZBH2012001 were also assessed. RESULTS: ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels. Data from behavioral tests indicated that ZBH2012001 exhibited superior antidepressant-like effects compared with duloxetine (one of the most used SNRIs) in the three depression models. The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg. CONCLUSION: These findings suggest that ZBH2012001 is a novel SNRI with superior antidepressant-like effects, lower acute toxicity and a better pharmacokinetic profile compared with duloxetine. Thus, ZBH2012001 may have potential therapeutic effects in depression disorders.
Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Analysis of Variance , Animals , Antidepressive Agents/chemistry , Benzodioxoles/pharmacology , Benzodioxoles/therapeutic use , Calcium/metabolism , Cyclic AMP/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Duloxetine Hydrochloride/pharmacology , HEK293 Cells , Helplessness, Learned , Hindlimb Suspension , Humans , Inhibitory Concentration 50 , Locomotion/drug effects , Male , Mice , Mice, Inbred ICR , Protein Binding/drug effects , Rats , Rats, Sprague-Dawley , Serotonin and Noradrenaline Reuptake Inhibitors/chemistry , Swimming/psychology , Thiophenes/pharmacology , Thiophenes/therapeutic useABSTRACT
Chronic hepatitis B virus (HBV) infection may lead to liver cirrhosis and hepatocellular carcinoma, but few drugs are available for its treatment. Acyclic nucleoside phosphonates (ANPs) have remarkable antivirus activities but are not easily absorbed from the gastrointestinal tract and accumulate in the kidneys, resulting in nephrotoxicity. Therefore, there is a need to find effective liver site-specific prodrugs. The dipivaloyloxymethyl ester of 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-adefovir dipivoxil (ADV)-is a first-line therapy drug for chronic hepatitis B with a low therapeutic index because of renal toxicity and low hepatic uptake. In this study, a series of PMEA derivatives were synthesized to enhance plasma stability and liver release. The metabolic stability of ADV (Chemical I) and its two analogues (Chemicals II and III) was evaluated in rat plasma and liver homogenate in vitro. An ion-pair reverse-phase HPLC-UV method and a hybrid ion trap and high-resolution time-of-flight mass spectrometry (LC-IT-TOF-MS) were used to evaluate the degradation rate of the analogues and to identify their intermediate metabolites, respectively. Chemicals I and II were hydrolyzed by cleavage of the C-O bond to give monoesters. Sufficient enzymatic activation in the liver homogenate through a relatively simple metabolic pathway, in addition to a favorable stability profile in rat plasma, made Chemical II an optimal candidate. Next, six analogues based on the structure of Chemical II were synthesized and evaluated in plasma and liver homogenate. Compared to Chemical II, these compounds generated less active PMEA levels in rat liver homogenate. Therefore, chemical modification of Chemical II may lead to new promising PMEA derivatives with enhanced plasma stability and liver activation.
Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/blood , Antiviral Agents/chemical synthesis , Hepatitis B virus/drug effects , Liver/drug effects , Organophosphonates/blood , Organophosphonates/chemical synthesis , Adenine/blood , Adenine/chemical synthesis , Adenine/pharmacology , Animals , Antiviral Agents/pharmacology , Biotransformation , Chromatography, High Pressure Liquid , Drug Evaluation, Preclinical , Drug Liberation , Drug Stability , Esters , In Vitro Techniques , Liver/metabolism , Molecular Structure , Organophosphonates/pharmacology , Rats , Spectrometry, Mass, Electrospray IonizationABSTRACT
Depression is a severe mood disorder with increasing morbidity and suicidality, while the current therapy is not satisfactory. Serotonin and noradrenaline reuptake inhibitors (SNRIs) have been reported to have higher efficacy and/or faster acting rate than commonly used antidepressants. The present study was designed to screen the potential SNRIs, using in vitro radioligand receptor binding assays and in vivo animal tests, and introduced the discovery of 071031B. In the tail suspension test and forced swimming test in mice, six compounds (071017S, 071026W, 071031A, 071031B, 080307A and 080307B) showed robust antidepressant activity, without stimulant effect on the locomotor activity or other side effects, and the minimal effective dose of 071017S, 071026W, 071031A and 071031B was less than that of duloxetine; in vitro binding tests indicated that 071031B had high affinity to both serotonin transporter and noradrenaline transporter with similar inhibitory rates to duloxetine at 1 and 100 nM; acute toxicity test indicated that the LD50 value of 071031B was similar to that of duloxetine. These findings demonstrated that this integrated system, combining high throughput screening technology and in vivo animal tests, is effective to screen potential monoamine reuptake inhibitors fast and accurately; 071031B is expected to be a novel serotonin and noradrenaline reuptake inhibitor for its robust antidepressant activity and transporter affinity.